Dostarlimab

• Description :

  Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively[1].

• Product Name Alternative :

  TSR-042; ANB-011; WBP-285

• UNSPSC :

  12352203

• Target :

  PD-1/PD-L1

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/dostarlimab.html

• Purity :

  98.92

• Solubility :

  H2O

• Smiles :

  [Dostarlimab]

• Molecular Weight :

  (144.18 kDa)

• References & Citations :

  [1]Kumar S, et al. Preclinical characterization of dostarlimab, a therapeutic anti-PD-1 antibody with potent activity to enhance immune function in in vitro cellular assays and in vivo animal models. MAbs. 2021 Jan-Dec;13 (1) :1954136.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Launched

• CAS Number :

  [2022215-59-2]